266 related articles for article (PubMed ID: 33678523)
1. Long-term impact of early initiation of enzyme replacement therapy in 34 MPS VI patients: A resurvey study.
Horovitz DDG; Leão EKEA; Ribeiro EM; Martins AM; Barth AL; Neri JICF; Kerstenetzky M; Siqueira ACM; Ribeiro BFR; Kim CA; Santos FC; Franco JFS; Lichtvan LCL; Giuliani LR; Rodrigues MDCS; Bonatti RCF; Teixeira TB; Gonçalves A; Lourenço CM; Pereira ASS; Acosta AX
Mol Genet Metab; 2021 May; 133(1):94-99. PubMed ID: 33678523
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes of patients with mucopolysaccharidosis VI treated with galsulfase enzyme replacement therapy since infancy.
Garcia P; Phillips D; Johnson J; Martin K; Randolph LM; Rosenfeld H; Harmatz P
Mol Genet Metab; 2021 May; 133(1):100-108. PubMed ID: 33775523
[TBL] [Abstract][Full Text] [Related]
3. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study.
Giugliani R; Lampe C; Guffon N; Ketteridge D; Leão-Teles E; Wraith JE; Jones SA; Piscia-Nichols C; Lin P; Quartel A; Harmatz P
Am J Med Genet A; 2014 Aug; 164A(8):1953-64. PubMed ID: 24764221
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI.
Horovitz DD; Magalhães TS; Acosta A; Ribeiro EM; Giuliani LR; Palhares DB; Kim CA; de Paula AC; Kerstenestzy M; Pianovski MA; Costa MI; Santos FC; Martins AM; Aranda CS; Correa Neto J; Holanda GB; Cardoso L; da Silva CA; Bonatti RC; Ribeiro BF; Rodrigues Mdo C; Llerena JC
Mol Genet Metab; 2013 May; 109(1):62-9. PubMed ID: 23535281
[TBL] [Abstract][Full Text] [Related]
5. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI.
Brunelli MJ; Atallah ÁN; da Silva EM
Cochrane Database Syst Rev; 2016 Mar; 3():CD009806. PubMed ID: 26943923
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI.
Brunelli MJ; Atallah ÁN; da Silva EM
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD009806. PubMed ID: 34533215
[TBL] [Abstract][Full Text] [Related]
7. The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).
Harmatz P; Hendriksz CJ; Lampe C; McGill JJ; Parini R; Leão-Teles E; Valayannopoulos V; Cole TJ; Matousek R; Graham S; Guffon N; Quartel A;
Mol Genet Metab; 2017 Sep; 122(1-2):107-112. PubMed ID: 28457718
[TBL] [Abstract][Full Text] [Related]
8. Enzyme replacement therapy outcomes across the disease spectrum: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program.
Harmatz PR; Lampe C; Parini R; Sharma R; Teles EL; Johnson J; Sivam D; Sisic Z
J Inherit Metab Dis; 2019 May; 42(3):519-526. PubMed ID: 30834539
[TBL] [Abstract][Full Text] [Related]
9. Enzyme replacement therapy initiated in adulthood: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program.
Lampe C; Harmatz PR; Parini R; Sharma R; Teles EL; Johnson J; Sivam D; Sisic Z
Mol Genet Metab; 2019 Aug; 127(4):355-360. PubMed ID: 31324526
[TBL] [Abstract][Full Text] [Related]
10. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase.
Harmatz P; Ketteridge D; Giugliani R; Guffon N; Teles EL; Miranda MC; Yu ZF; Swiedler SJ; Hopwood JJ;
Pediatrics; 2005 Jun; 115(6):e681-9. PubMed ID: 15930196
[TBL] [Abstract][Full Text] [Related]
11. Up to five years experience with 11 mucopolysaccharidosis type VI patients.
Brands MM; Oussoren E; Ruijter GJ; Vollebregt AA; van den Hout HM; Joosten KF; Hop WC; Plug I; van der Ploeg AT
Mol Genet Metab; 2013 May; 109(1):70-6. PubMed ID: 23523338
[TBL] [Abstract][Full Text] [Related]
12. Retrospective chart review of urinary glycosaminoglycan excretion and long-term clinical outcomes of enzyme replacement therapy in patients with mucopolysaccharidoses.
Jones SA; Marsden D; Koutsoukos T; Sniadecki J; Tylee K; Phillippo S; Kakkis E
Mol Genet Metab; 2020 Aug; 130(4):255-261. PubMed ID: 32563631
[TBL] [Abstract][Full Text] [Related]
13. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI.
Furujo M; Kubo T; Kosuga M; Okuyama T
Mol Genet Metab; 2011 Dec; 104(4):597-602. PubMed ID: 21930407
[TBL] [Abstract][Full Text] [Related]
14. Clinical and event-based outcomes of patients with mucopolysaccharidosis VI receiving enzyme replacement therapy in Turkey: a case series.
İnci A; Okur İ; Tümer L; Biberoğlu G; Öktem M; Ezgü F
Orphanet J Rare Dis; 2021 Oct; 16(1):438. PubMed ID: 34666789
[TBL] [Abstract][Full Text] [Related]
15. Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase.
Brands MM; Hoogeveen-Westerveld M; Kroos MA; Nobel W; Ruijter GJ; Özkan L; Plug I; Grinberg D; Vilageliu L; Halley DJ; van der Ploeg AT; Reuser AJ
Orphanet J Rare Dis; 2013 Apr; 8():51. PubMed ID: 23557332
[TBL] [Abstract][Full Text] [Related]
16. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis VI: clinical facts and figures.
Harmatz P
Turk J Pediatr; 2010; 52(5):443-9. PubMed ID: 21434527
[TBL] [Abstract][Full Text] [Related]
17. Genotypic-phenotypic features and enzyme replacement therapy outcome in patients with mucopolysaccharidosis VI from Turkey.
Kılıç M; Dursun A; Coşkun T; Tokatlı A; Özgül RK; Yücel-Yılmaz D; Karaca M; Doğru D; Alehan D; Kadayıfçılar S; Genç A; Turan-Dizdar H; Gönüldaş B; Savcı S; Sağlam M; Aksoy C; Arslan U; Sivri HS
Am J Med Genet A; 2017 Nov; 173(11):2954-2967. PubMed ID: 28884960
[TBL] [Abstract][Full Text] [Related]
18. Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP).
Hendriksz CJ; Giugliani R; Harmatz P; Lampe C; Martins AM; Pastores GM; Steiner RD; Leão Teles E; Valayannopoulos V;
J Inherit Metab Dis; 2013 Mar; 36(2):373-84. PubMed ID: 22127392
[TBL] [Abstract][Full Text] [Related]
19. Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI): a single dose of galsulfase further reduces urine glycosaminoglycans after hematopoietic stem cell transplantation.
Whitley CB; Utz JR
Mol Genet Metab; 2010 Dec; 101(4):346-8. PubMed ID: 20800524
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations.
Ruane T; Haskins M; Cheng A; Wang P; Aguirre G; Knox VW; Qi Y; Tompkins T; O'Neill CA
Mol Genet Metab; 2016 Feb; 117(2):157-63. PubMed ID: 26776148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
